IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice

Oncoimmunology. 2020 Aug 20;9(1):1806662. doi: 10.1080/2162402X.2020.1806662.


The metabolic gene isocitrate dehydrogenase 1 (IDH1) is commonly mutated in lower grade glioma (LGG) and secondary glioblastoma (GBM). Regulatory T cells (Tregs) play a significant role in the suppression of antitumor immunity in human glioma. Given the importance of Tregs in the overall framework of designing immune-based therapies, a better understanding on their association with IDH mutational status remains of critical clinical importance. Using multispectral imaging analysis, we compared the incidence of Tregs in IDH-mutant and IDH wild-type glioma from patient tumor samples of LGG. An orthotopic IDH-mutant murine model was generated to evaluate the role of mutant IDH on Treg infiltration by immunohistochemistry. When compared to IDH wild-type controls, Tregs are disproportionally underrepresented in mutant disease, even when taken as a proportion of all infiltrating T cells. Our findings suggest that therapeutic agents targeting Tregs may be more appropriate in modulating the immune response to wild-type disease.

Keywords: Glioma; IDH-mutation; Regulatory T cells; immune microenvironment.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Brain Neoplasms* / genetics
  • Glioma* / genetics
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Mice
  • Mutation
  • T-Lymphocytes, Regulatory


  • Isocitrate Dehydrogenase